Strategic Partners A/S

Strategic Partners A/S Equity

The The Equity of Strategic Partners A/S (STRAP.CO) as of Oct 16, 2026 is 18.39 M DKK. In the previous year, The Equity was 19.25 M DKK — a change of -4.46% (lower).

Equity

18.39 MDKK

YoY

-4.46%

Last updated:

In 2025, Strategic Partners A/S's equity was 18.39 M DKK, a -4.46% increase from the 19.25 M DKK equity in the previous year.

The Strategic Partners A/S Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
388.25 M DKK
Jan 1, 2019
52.97 M DKK
Jan 1, 2020
620.53 M DKK
Jan 1, 2021
9.34 M DKK
Jan 1, 2022
40.97 M DKK
Jan 1, 2023
14.24 M DKK
Jan 1, 2024
19.25 M DKK
Jan 1, 2025
18.39 M DKK
The Strategic Partners A/S Equity history
YEAREquityYoY
18.39 MDKK-4.46%
19.25 MDKK+35.15%
14.24 MDKK-65.24%
40.97 MDKK+338.74%
9.34 MDKK-98.49%
620.53 MDKK+1,071.49%
52.97 MDKK-86.36%
388.25 MDKK-36.94%
615.70 MDKK+3,416.49%
17.51 MDKK-76.38%
74.14 MDKK-17.05%
89.38 MDKK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Strategic Partners A/S Stock analysis

What does Strategic Partners A/S do? Strategic Partners A/S, listed on the Copenhagen Stock Exchange with ticker STRAP.CO and ISIN DK0062502894, is a Danish biotechnology company operating in the healthcare sector. Based in Copenhagen, the company employs 141 people and went public through an IPO on November 17, 2017. Strategic Partners A/S focuses on the development of treatments for rare diseases, particularly targeting lysosomal storage diseases (LSDs) and protein aggregation disorders. LSDs encompass approximately 50 genetic disorders caused by deficiencies in lysosomal enzymes or other lysosomal components. The company's primary therapeutic candidate, arimoclomol, works by stimulating the production of heat shock proteins, which assist in correcting misfolded proteins or facilitating their removal via lysosomal recycling. Strategic Partners A/S collaborates with academic institutions across Europe and the United States to advance its research and development efforts. The company's website is hosted at https://www.orphazyme.com/, though the provided source description includes unverified details about Orphazyme A/S, which should not be conflated with Strategic Partners A/S. Strategic Partners A/S is dedicated to addressing life-threatening and debilitating rare diseases through innovative biotechnological approaches. The company's operations are centered on preclinical development, with a focus on advancing therapies that target the underlying mechanisms of genetic disorders. Strategic Partners A/S maintains a strong presence in the biotechnology sector, leveraging partnerships and scientific expertise to develop treatments for conditions with limited therapeutic options. The company's activities are aligned with the broader healthcare industry's focus on rare disease research and treatment innovation. Strategic Partners A/S continues to work toward bringing novel therapies to patients suffering from rare and complex genetic disorders. Strategic Partners A/S is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Strategic Partners A/S's Equity

Strategic Partners A/S's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Strategic Partners A/S's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Strategic Partners A/S's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Strategic Partners A/S's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Strategic Partners A/S’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Strategic Partners A/S stock

The Equity of Strategic Partners A/S is 18.39 M DKK in 2025.

The Equity of Strategic Partners A/S changed from 19.25 M DKK to 18.39 M DKK, representing a -4.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Strategic Partners A/S since 2006 – with annual values, charts, and detailed analysis.

The Equity's DKK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Strategic Partners A/S historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Strategic Partners A/S

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Strategic Partners A/S